Comparison of dermatan sulfate and heparan sulfate concentrations in serum, cerebrospinal fluid and urine in patients with mucopolysaccharidosis type I receiving intravenous and intrathecal enzyme replacement therapy

2020 ◽  
Vol 508 ◽  
pp. 179-184
Author(s):  
Haoyue Zhang ◽  
Patricia I. Dickson ◽  
Ashlee R. Stiles ◽  
Agnes H. Chen ◽  
Steven Q. Le ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Enzyme Replacement Therapy ◽  
Heparan Sulfate ◽  
Replacement Therapy ◽  
Dermatan Sulfate ◽  
Type I ◽  
Mucopolysaccharidosis Type ◽  
Mucopolysaccharidosis Type I ◽  
Enzyme Replacement

Induction of immune tolerance to enzyme replacement therapy in mucopolysaccharidosis type I

2018 ◽  
Vol 123 (2) ◽  
pp. S86
Author(s):  
Ai Yin Liao ◽  
Arunabha Ghosh ◽  
Claire O'Leary ◽  
Jean Mercer ◽  
Heather J. Church ◽  
...  
Keyword(s):  
Enzyme Replacement Therapy ◽  
Replacement Therapy ◽  
Immune Tolerance ◽  
Type I ◽  
Mucopolysaccharidosis Type ◽  
Mucopolysaccharidosis Type I ◽  
Enzyme Replacement

Progressive eye pathology in mucopolysaccharidosis type I mice and effects of enzyme replacement therapy

2020 ◽  
Vol 48 (3) ◽  
pp. 334-342
Author(s):  
Esteban A. Gonzalez ◽  
Fernanda Visioli ◽  
Gabriela Pasqualim ◽  
Carolina F. M. Souza ◽  
Diane R. Marinho ◽  
...  
Keyword(s):  
Enzyme Replacement Therapy ◽  
Replacement Therapy ◽  
Type I ◽  
Mucopolysaccharidosis Type ◽  
Mucopolysaccharidosis Type I ◽  
Enzyme Replacement
Sign in / Sign up

Export Citation Format

Share Document